Business Context and Reporting Period
This Form 8-K Current Report was filed by Eli Lilly and Company on November 19, 2024. The filing addresses corporate governance changes, specifically the election of a new director and the resignation of an existing director, effective in December 2024.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the composition of the Board of Directors:
- Appointment: Jon Moeller was elected as a new member of the Board, effective December 1, 2024. He is currently the Chairman, President, and CEO of Procter & Gamble.
- Resignation: Karen Walker notified the Board of her resignation, effective December 31, 2024. She has served on the Board since 2018.
Outlook, Commentary, and Risks
Management Commentary: The Board determined Mr. Moeller is independent under NYSE standards. He will serve on the Audit Committee and the Directors and Corporate Governance Committee. Ms. Walker's resignation did not arise from any disagreement with the Company regarding operations, policies, or practices.
Future Collaboration: Starting in 2025, Ms. Walker is expected to collaborate with the Company on certain digital commercial activities.
Compensation: Mr. Moeller will participate in the Company's standard director compensation program.
Key Facts for Investor Verification
- Jon Moeller's effective start date as a director is December 1, 2024.
- Karen Walker's effective resignation date is December 31, 2024.
- Mr. Moeller will stand for election by shareholders at the annual meeting in May 2026.
- Ms. Walker will transition to a collaborative role on digital commercial activities in 2025.
- No financial data or guidance is included in this specific filing.